ASND
Ascendis Pharma AS
227.90$
+0.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 83.9% | 85.1% | 82.8% | 82.7% | 89.0% | 89.9% | 86.8% | 87.6% | 88.1% | 85.1% | 56.0% | 60.8% | |
| 50.5% | 47.5% | 39.9% | 34.1% | 57.2% | 47.4% | 48.8% | 45.4% | 46.7% | 47.3% | 28.6% | 35.5% | |
| 52.2% | 48.4% | 39.9% | 34.1% | 57.2% | 47.4% | 48.8% | 45.4% | 46.7% | 47.3% | 28.6% | 35.5% | |
| 3.1% | 4.3% | 5.1% | 6.5% | 3.0% | 14.1% | 6.3% | 10.2% | 12.8% | 12.1% | 9.8% | 9.8% | |
| 21.7% | 25.3% | 29.0% | 33.1% | 24.3% | 25.1% | 27.6% | 27.9% | 26.2% | 23.1% | 15.7% | 13.6% | |
| 14.4% | – | – | – | – | – | – | – | – | – | – | – | |
| – | 0.4% | – | – | – | 0.3% | – | – | – | 0.3% | 0.2% | – | |
| 0.5% | 0.1% | 0.5% | 0.6% | 0.4% | 0.0% | 0.4% | 0.3% | 0.3% | 0.0% | – | 0.2% | |
| 108.4% | 117.6% | 129.7% | 142.3% | 108.9% | 109.0% | 117.9% | 117.2% | 115.1% | 112.5% | 75.6% | 37.2% | |
| 24.4% | 89.2% | 99.6% | 111.8% | 76.7% | 77.0% | 83.4% | 85.9% | 85.4% | 82.1% | 56.2% | 20.3% | |
| 3.0% | 52.7% | 54.8% | 59.8% | 41.1% | 41.7% | 46.2% | 42.5% | 41.8% | 37.4% | 25.5% | 2.9% | |
| 13.9% | 11.5% | 11.8% | 13.1% | 6.9% | 8.2% | 7.9% | 8.6% | 6.8% | 7.0% | 3.9% | 4.5% | |
| 62.9% | 64.7% | 28.6% | 28.9% | 31.0% | 31.0% | 33.7% | 30.4% | 28.7% | 29.6% | 19.3% | 16.8% | |
| -8.4% | -17.6% | -29.7% | -42.3% | -8.9% | -9.0% | -17.9% | -17.2% | -15.1% | -12.5% | 24.4% | 62.8% | |
| -252.4% | -275.8% | -297.9% | -326.3% | -232.9% | -217.0% | -250.4% | -245.1% | -234.3% | -207.3% | -104.0% | -82.2% | |
| 6.4% | 6.9% | 7.1% | 7.6% | 5.4% | 5.1% | 5.7% | 5.9% | 5.3% | 4.7% | 3.2% | 3.0% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.